$581 Million is the total value of Fairmount Funds Management LLC's 16 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | AXSOME THERAPEUTICS INC | $124,078,387 | -20.0% | 2,011,647 | 0.0% | 21.34% | -13.3% | |
| Buy | NUVALENT INC | $75,256,396 | -9.4% | 2,884,492 | +3.4% | 12.94% | -1.8% | |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $62,798,774 | -16.4% | 3,127,429 | +8.8% | 10.80% | -9.4% |
| BGNE | BEIGENE LTDsponsored adr | $51,607,150 | -2.0% | 239,443 | 0.0% | 8.88% | +6.2% | |
| New | ENLIVEN THERAPEUTICS INC | $42,156,142 | – | 1,924,938 | +100.0% | 7.25% | – | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $34,843,209 | -12.9% | 1,369,623 | 0.0% | 5.99% | -5.6% | |
| COGT | COGENT BIOSCIENCES INC | $29,769,340 | -6.7% | 2,758,975 | 0.0% | 5.12% | +1.2% | |
| ARGX | ARGENX SEsponsored adr | $27,394,317 | -1.6% | 73,526 | 0.0% | 4.71% | +6.6% | |
| ASTRIA THERAPEUTICS INC | $25,288,580 | -10.7% | 1,901,397 | 0.0% | 4.35% | -3.2% | ||
| TERN | TERNS PHARMACEUTICALS INC | $24,153,600 | +16.3% | 2,040,000 | 0.0% | 4.15% | +26.1% | |
| TYRA BIOSCIENCES INC | $22,771,158 | +111.4% | 1,416,998 | 0.0% | 3.92% | +129.3% | ||
| New | THESEUS PHARMACEUTICALS INC | $16,567,158 | – | 1,865,671 | +100.0% | 2.85% | – | |
| GERN | New | GERON CORP | $15,416,457 | – | 7,104,358 | +100.0% | 2.65% | – |
| DBVT | DBV TECHNOLOGIES SAsponsored adr | $11,939,789 | +10.5% | 7,064,964 | 0.0% | 2.05% | +19.7% | |
| TRVI | TREVI THERAPEUTICS INC | $10,538,553 | -4.1% | 5,696,515 | 0.0% | 1.81% | +3.9% | |
| MRUS | New | MERUS N V | $6,889,604 | – | 374,435 | +100.0% | 1.18% | – |
| IMRA | Exit | IMARA INC | $0 | – | -631,333 | -100.0% | -0.41% | – |
| ANNX | Exit | ANNEXON INC | $0 | – | -3,358,563 | -100.0% | -2.76% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -2,543,107 | -100.0% | -4.63% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -283,000 | -100.0% | -5.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.